| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/11/2001 | EP1090012A1 Inhibitors of prenyl-protein transferase |
| 04/11/2001 | EP1090011A1 Inhibitors of prenyl-protein transferase |
| 04/11/2001 | EP1090010A1 Thienopyridine compounds, their production and use |
| 04/11/2001 | EP1090009A2 Cell adhesion-inhibiting antinflammatory compounds |
| 04/11/2001 | EP1090008A1 Syntheses of a variety of lamellarin compounds and analogues |
| 04/11/2001 | EP1090006A1 Alkyl ether analogs of chlorins having an n-substituted imide ring |
| 04/11/2001 | EP1090004A1 A substituted triazolo-pyridazine derivative, pharmaceutical compositions made therefrom |
| 04/11/2001 | EP1090003A1 7-alkyl- and cycloalkyl-substituted imidazotriazinones |
| 04/11/2001 | EP1090001A1 (heterocyclic)methyl substituted carbapenem antibacterials |
| 04/11/2001 | EP1090000A1 Naphtho 1,8-de]thiasin-2-yl methyl carbapenem antibacterials |
| 04/11/2001 | EP1089999A1 (heterocyclic) methyl substituted carbapenem antibacterials |
| 04/11/2001 | EP1089998A2 Epothilone derivatives and their synthesis and use |
| 04/11/2001 | EP1089997A1 4,5,6 and 7-indole and indoline derivatives, their preparation and use |
| 04/11/2001 | EP1089996A1 Paroxetine methanesulfonate |
| 04/11/2001 | EP1089995A1 Paroxetine ascorbate |
| 04/11/2001 | EP1089994A1 Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same |
| 04/11/2001 | EP1089993A1 5-ht 1f? agonists |
| 04/11/2001 | EP1089990A1 1-(benzothiazol-2-yl)-4-(1-phenylmethyl)piperazines: dopamine receptor subtype specific ligands |
| 04/11/2001 | EP1089989A1 Inhibitors of alpha4beta1 mediated cell adhesion |
| 04/11/2001 | EP1089981A1 Compounds for inhibiting beta-amyloid peptide release and/or its synthesis. |
| 04/11/2001 | EP1089980A1 Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
| 04/11/2001 | EP1089977A1 Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
| 04/11/2001 | EP1089973A1 Amidino and guanidino azetidinone tryptase inhibitors |
| 04/11/2001 | EP1089970A2 Oxidation inhibitors for prostane derivatives |
| 04/11/2001 | EP1089969A1 Stable no-delivering compounds |
| 04/11/2001 | EP1089968A1 Thyroid hormone analogues and methods for their preparation |
| 04/11/2001 | EP1089964A1 Hydrazine derivatives |
| 04/11/2001 | EP1089963A1 Hydroxamic acid derivatives as inhibitors of the production of human cd23 and of the tnf release |
| 04/11/2001 | EP1089962A1 2-fluoro-2-alkyl alkanoamides with anticonvulsant activity |
| 04/11/2001 | EP1089961A1 Benflumetol derivatives, intermediates thereof and their use against parasitical protozoa and trematodes |
| 04/11/2001 | EP1089794A2 Methods for inhibiting tef-3 activity |
| 04/11/2001 | EP1089764A2 A method for stimulating the immune system |
| 04/11/2001 | EP1089763A2 Agents for specifically inhibiting osteoclastic bone resorption |
| 04/11/2001 | EP1089761A2 Medicaments containing bisphosphonic acids and derivatives thereof which are provided for preventing and treating autoimmune diseases and allergies |
| 04/11/2001 | EP1089750A1 Compositions and methods for inhibiting bone resorption |
| 04/11/2001 | EP1089748A1 Water-soluble native dry plant extract, especially ginkgo biloba extract with a high terpenoid and flavone glycoside content |
| 04/11/2001 | EP1089747A1 Compounds obtained from salvia species having antiviral activity |
| 04/11/2001 | EP1089746A1 Extracts of hypericum perforatum and formulations containing them |
| 04/11/2001 | EP1089745A1 Oregano for the treatment of internal parasites and protozoa |
| 04/11/2001 | EP1089744A2 Neuroprotective composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression, comprising acetyl-l-carnitine and hypericin |
| 04/11/2001 | EP1089742A2 Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome, comprising propionyl-l-carnitine and genistein |
| 04/11/2001 | EP1089741A1 Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv |
| 04/11/2001 | EP1089740A1 TREATMENT OF $i(C. DIFFICILE) TOXIN B ASSOCIATED CONDITIONS |
| 04/11/2001 | EP1089739A1 Cyclophosphamide coated tablets |
| 04/11/2001 | EP1089738A1 Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof |
| 04/11/2001 | EP1089737A2 Method of treating pulmonary hypertension |
| 04/11/2001 | EP1089736A2 Method and compositions for the treatment or amelioration of female sexual dysfunction |
| 04/11/2001 | EP1089735A1 4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists |
| 04/11/2001 | EP1089734A2 Use of tempo and tempo derivatives for inducing cell death |
| 04/11/2001 | EP1089733A2 Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders |
| 04/11/2001 | EP1089732A1 Compositions and methods for treating elevated blood cholesterol |
| 04/11/2001 | EP1089731A1 Compositions and methods for treating elevated blood cholesterol |
| 04/11/2001 | EP1089730A1 Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment |
| 04/11/2001 | EP1089729A1 Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment |
| 04/11/2001 | EP1089728A1 Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide |
| 04/11/2001 | EP1089727A1 Liposomal formulations of busulphan |
| 04/11/2001 | EP1089726A2 Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid |
| 04/11/2001 | EP1089725A1 The use of valproic acid analog for the treatment and prevention of migraine and affective illness |
| 04/11/2001 | EP1089724A1 Therapeutic compositions and methods of use |
| 04/11/2001 | EP1089723A1 Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| 04/11/2001 | EP1089722A1 Matrix-type transdermal patch for steroid hormones |
| 04/11/2001 | EP1089720A1 Transdermal therapeutic system containing hormones and crystallization inhibitors |
| 04/11/2001 | EP1089719A2 Transdermal therapeutic system containing hormones and crystallization inhibitors |
| 04/11/2001 | EP1089715A1 Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| 04/11/2001 | EP1089714A2 Processes to generate submicron particles of water-insoluble compounds |
| 04/11/2001 | EP1089713A1 Temperature-sensitive liposomal formulation |
| 04/11/2001 | EP1089712A2 Large porous particles emitted from an inhaler |
| 04/11/2001 | EP1089710A1 Injectable pharmaceutical formulations of partricin derivatives |
| 04/11/2001 | EP1089679A1 A device and method for the treatment of erectile dysfunction |
| 04/11/2001 | EP1089620A1 Hydrophilic polymer blends used to prevent cow skin infections |
| 04/11/2001 | EP1068192A4 Novel crystalline complexes of baccatin iii with imidazole, 2-methylimidazole or isopropanol |
| 04/11/2001 | EP1056736A4 Alternate method for acylating 10-deacetylbaccatin iii selectively at the c-10 position |
| 04/11/2001 | EP1047682A4 Recovery of taxanes from plant material |
| 04/11/2001 | EP1021176A4 Cobalt schiff base compounds |
| 04/11/2001 | EP0984963B1 Novel compounds |
| 04/11/2001 | EP0963203A4 Mammalian tolloid-like gene and protein |
| 04/11/2001 | EP0936866A4 Compounds, compositions and methods for treating antibiotic-resistant infections |
| 04/11/2001 | EP0873317B1 Pyrimidin derivatives |
| 04/11/2001 | EP0866704B1 Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis |
| 04/11/2001 | EP0854709B1 Use of boswellic acid and its derivatives for inhibiting normal and increased leucocytic elastase or plasmin activity |
| 04/11/2001 | EP0775113B1 N-substituted azabicycloheptane derivatives useful as neuroleptics |
| 04/11/2001 | EP0662076B1 2-aminoalkyl-5-aminoalkylamino substituted isoquinoindazole-6-(2h)-ones with antitumour activity |
| 04/11/2001 | CN1291239A Fermentative preparation process for cytostatics and crystal form thereof |
| 04/11/2001 | CN1291238A Process for obtaining of HMG-CO A reductase inhibitors of high purify |
| 04/11/2001 | CN1291231A Human telomerase catalytic subunit |
| 04/11/2001 | CN1291228A Enzyme catalyzed therapeutic agents |
| 04/11/2001 | CN1291198A Three-dimesional structures and models of Fc receptors and use thereof |
| 04/11/2001 | CN1291196A Nevol anti-estrogenic steroids, and associated pharmaceutical compositions and method of use |
| 04/11/2001 | CN1291194A Substituted 1,2,4-triazolo [3,4-a] pyridazine |
| 04/11/2001 | CN1291193A Novel triazolo (4.5-d) pyrimidine compounds |
| 04/11/2001 | CN1291190A 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonist |
| 04/11/2001 | CN1291189A 9-aminoacridine derivatives and process for the preparation thereof |
| 04/11/2001 | CN1291188A Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia |
| 04/11/2001 | CN1291186A Cyclic amide compounds |
| 04/11/2001 | CN1291185A Phtalimido arylpiperazines as alpha IA receptor antagonists useful in the treatment of benign prostatic hyperplasia |
| 04/11/2001 | CN1291184A Cycloalkene derivatives, process for producing the same and use |
| 04/11/2001 | CN1291183A N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl-3-substituted-alkyl, aryl or heteroarylamides) as matrix metallo protein inhibitors |
| 04/11/2001 | CN1291178A E-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl) phenoxy] ethanol and pharmaceutical compositions thereof |
| 04/11/2001 | CN1291102A Pharmaceutical preparation for selectively supplementing oestrogen deficiency in the central nervous system |
| 04/11/2001 | CN1291101A Regulation of estrus and ovulation in gilts |